Characteristics and Outcomes of Patients With Sarcoidosis Listed for Lung Transplantation

Arcasoy, Selim M.; Christie, Jason D.; Pochettino, Alberto; Rosengard, Bruce R.; Blumenthal, Nancy P.; Bavaria, Joseph E.; Kotloff, Robert M.

doi:10.1378/chest.120.3.873

Cited by 160 publications

(125 citation statements)

References 16 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…These factors include the presence of hypoxemia, mPAP above 35 mmHg, a cardiac index below 2 L/min/m 2 , and high right atrial pressure ≥ 15 Hg. (Arcasoy et al, 2001;Shorr et al, 2002) 9. Conclusion SAPH is common in advanced sarcoidosis, although it can be found in earlier stages of the disease as well.…”

Section: Prognosismentioning

confidence: 99%

Sarcoidosis Associated Pulmonary Hypertension

Palmero¹,

Factor²,

Sulica³

2011

Pulmonary Hypertension - From Bench Research to Clinical Challenges

View full text Add to dashboard Cite

Section: Prognosismentioning

confidence: 99%

Sarcoidosis Associated Pulmonary Hypertension

Palmero¹,

Factor²,

Sulica³

2011

Pulmonary Hypertension - From Bench Research to Clinical Challenges

View full text Add to dashboard Cite

“…Listing policy, however, is difficult to codify because of varied pathogenesis and often unpredictable natural histories. As mentioned previously, the current system exerts pressure to place patients on the waiting list at earlier stages of lung disease in response to longer average times to organ availability, as has been commented on recently in the context of cystic fibrosis, pulmonary fibrosis, and sarcoidosis (14)(15)(16)(17)(18). These trends toward earlier diagnosis and more broadly defined criteria for adding patients to the waiting list are not without potential consequences.…”

Section: Lung Transplant Recipient Characteristicsmentioning

confidence: 99%

Thoracic organ transplantation

Pierson

Barr

McCullough

et al. 2004

American Journal of Transplantation

View full text Add to dashboard Cite

This article presents an overview of factors associated with thoracic transplantation outcomes over the past decade and provides valuable information regarding the heart, lung, and heart-lung waiting lists and thoracic organ transplant recipients. Waiting list and post-transplant information is used to assess the importance of patient demographics, risk factors, and primary cardiopulmonary disease on outcomes.The time that the typical listed patient has been waiting for a heart, lung, or heart-lung transplant has markedly increased over the past decade, while the number of transplants performed has declined slightly and survival after transplant has plateaued. Waiting list mortality, however, appears to be declining for each organ and for most diseases and highseverity subgroups, perhaps in response to recent changes in organ allocation algorithms. Based on perceived inequity in organ access and in response to a mandate from Health Resources and Services Administration, the lung transplant community is Notes on Sources: The articles in this report are based on the reference tables in the 2003

show abstract

“…3 A chronic course occurs in 10-30% of patients, at times resulting in significant impairment of lung function. 4,5 In addition, sarcoidosis is a diagnosis of exclusion because it shares similarities with the clinical presentations of other lung diseases (such as tuberculosis [TB], fungal infections, lung cancer and cryptogenic organizing pneumonia) which results in a substantial challenge in differentiating sarcoidosis from other granulomatous lung diseases, especially in cases of smear-negative TB. [6][7][8] Sarcoidosis biomarkers are urgently needed, to deliver targeted therapies in individuals with complicated sarcoidosis and to identify patients at risk for other lung diseases.…”

Section: Introductionmentioning

confidence: 99%

Serum concentrations of A disintegrin and metalloproteinase 9 (ADAM9) mRNA as a promising novel marker for the detection of pulmonary sarcoidosis

et al. 2013

View full text Add to dashboard Cite

Aims: This prospective study investigated the potential role of serum A disintegrin and metalloproteinase 9 (ADAM9) mRNA in the differential diagnosis of pulmonary sarcoidosis from other diseases with similar clinical presentations, such as tuberculosis (TB). Methods: Serum samples were collected from patients with sarcoidosis, and compared with those from patients with TB and healthy control subjects. Real-time quantitative reverse transcription-polymerase chain reaction was performed to measure the concentration of ADAM9 mRNA relative to the internal control, glyceraldehyde-3-phosphate dehydrogenase. Results: A total of 100 patients with sarcoidosis were compared with 50 patients with TB and 50 healthy control subjects. The serum concentration of ADAM9 mRNA in patients with sarcoidosis was significantly lower than that in healthy control subjects and patients with TB. The serum concentration of ADAM9 mRNA in patients with TB was significantly higher than that in healthy control subjects. Conclusion: These data suggest that serum ADAM9 mRNA might be a potential biomarker for the differential diagnosis of pulmonary sarcoidosis. KeywordsPulmonary sarcoidosis, A disintegrin and metalloproteinase 9, ADAM9, serum concentration, quantitative reverse transcription-polymerase chain reaction Date

show abstract

Characteristics and Outcomes of Patients With Sarcoidosis Listed for Lung Transplantation

Cited by 160 publications

References 16 publications

Sarcoidosis Associated Pulmonary Hypertension

Sarcoidosis Associated Pulmonary Hypertension

Thoracic organ transplantation

Serum concentrations of A disintegrin and metalloproteinase 9 (ADAM9) mRNA as a promising novel marker for the detection of pulmonary sarcoidosis

Contact Info

Product

Resources

About